Romidepsin is a medication used in this clinical trial to treat a type of cancer called nodal peripheral T-cell lymphoma. It works by interfering with the growth of cancer cells, which may slow down or stop their spread in the body. In this study, Romidepsin is combined with other treatments to see if it can improve the outcomes for patients who are receiving it as a first-line treatment before undergoing a stem cell transplant.

CHOEP is a combination of chemotherapy drugs used to treat certain types of cancer, including lymphomas. CHOEP stands for Cyclophosphamide, Doxorubicin, Vincristine, Etoposide, and Prednisone. Each of these drugs works in a different way to stop the growth of cancer cells. Cyclophosphamide and Doxorubicin damage the DNA of cancer cells, Vincristine interferes with cell division, Etoposide blocks a specific enzyme needed for cancer cell growth, and Prednisone is a steroid that helps reduce inflammation and can also kill cancer cells. In this trial, CHOEP is used alongside Romidepsin to see if the combination is more effective in treating the lymphoma before a stem cell transplant.

Anaplastic Large T-cell Lymphoma ALK negative – This is a type of non-Hodgkin lymphoma that affects T-cells, which are part of the immune system. It is characterized by the absence of the anaplastic lymphoma kinase (ALK) protein. The disease typically presents with symptoms such as swollen lymph nodes, fever, and weight loss. It can progress by spreading to other parts of the body, including the skin, lungs, and liver. The progression involves the rapid growth of abnormal T-cells, which can lead to organ dysfunction. The disease is aggressive and requires careful monitoring.

Angioimmunoblastic T-cell Lymphoma – This is a rare and aggressive form of non-Hodgkin lymphoma that originates from T-cells. It is characterized by systemic symptoms such as fever, night sweats, and weight loss, along with generalized lymphadenopathy. The disease progresses by affecting the immune system, leading to immune dysfunction and increased susceptibility to infections. It can also cause skin rashes and autoimmune disorders. The progression involves the proliferation of atypical lymphoid cells and can affect multiple organs. The disease often leads to significant immune system impairment.

Peripheral T-cell Lymphoma, NOS – This is a diverse group of aggressive lymphomas that originate from mature T-cells. “NOS” stands for “not otherwise specified,” indicating that the lymphoma does not fit into other specific categories. The disease typically presents with symptoms such as enlarged lymph nodes, fever, and weight loss. It progresses by spreading to various parts of the body, including the liver, bone marrow, and skin. The progression involves the uncontrolled growth of abnormal T-cells, which can disrupt normal organ function. The disease is known for its aggressive nature and complex clinical presentation.